Supplementary Table 1 from Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression

Chelsey Burke; Tamar Y. Feinberg; Samantha Brosius; Umesh Kumar Bhanot; Mala Jain; Irina Linkov; Armaan H. Siddiquee; Kristina C. Guillan; Glorymar Ibáñez; Andoyo A. Ndengu; Paul Calder; Néstor Rosales; Diego F. Coutinho; Matthew M. Long; Raina Fishkin; Sheeno P. Thyparambil; Julia L. Glade Bender; Damon R. Reed; Daoqi You; Michael Vincent Ortiz; Emily Kanaya Slotkin; Andrew L. Kung; Filemon S. Dela Cruz

doi:10.1158/1535-7163.30986042

Supplementary Table 1 from Antitumor Activity of Trastuzumab Deruxtecan in Pediatric Solid Tumors with Variable HER2 Expression

2026 Open access

Read full text

Authors: Chelsey Burke, Tamar Y. Feinberg, Samantha Brosius, Umesh Kumar Bhanot, Mala Jain, Irina Linkov, Armaan H. Siddiquee, Kristina C. Guillan, Glorymar Ibáñez, Andoyo A. Ndengu, Paul Calder, Néstor Rosales

+11 more

Diego F. Coutinho, Matthew M. Long, Raina Fishkin, Sheeno P. Thyparambil, Julia L. Glade Bender, Damon R. Reed, Daoqi You, Michael Vincent Ortiz, Emily Kanaya Slotkin, Andrew L. Kung, Filemon S. Dela Cruz

DOI: 10.1158/1535-7163.30986042

Cited by: 0

Abstract

Supplementary Table 1. Cell line and growth media information.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Peptidase Inhibition and Analysis Neuroblastoma Research and Treatments

Publication details

Publisher: American Association for Cancer Research (AACR)
Publication date: 2 January 2026